X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 40.6 19.5 208.1% View Chart
P/BV x 3.7 4.6 80.7% View Chart
Dividend Yield % 0.5 0.9 51.3%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-18
CADILA HEALTHCARE
Mar-18
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs663558 118.8%   
Low Rs479362 132.5%   
Sales per share (Unadj.) Rs189.0116.3 162.6%  
Earnings per share (Unadj.) Rs17.617.9 98.5%  
Cash flow per share (Unadj.) Rs34.023.1 147.1%  
Dividends per share (Unadj.) Rs3.003.50 85.7%  
Dividend yield (eoy) %0.50.8 69.0%  
Book value per share (Unadj.) Rs176.785.4 206.9%  
Shares outstanding (eoy) m805.121,023.74 78.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.0 76.4%   
Avg P/E ratio x32.525.7 126.1%  
P/CF ratio (eoy) x16.819.9 84.4%  
Price / Book Value ratio x3.25.4 60.0%  
Dividend payout %17.119.6 87.0%   
Avg Mkt Cap Rs m459,724470,664 97.7%   
No. of employees `00023.611.8 199.8%   
Total wages/salary Rs m26,90118,545 145.1%   
Avg. sales/employee Rs Th6,446.110,072.7 64.0%   
Avg. wages/employee Rs Th1,139.41,569.1 72.6%   
Avg. net profit/employee Rs Th600.01,547.7 38.8%   
INCOME DATA
Net Sales Rs m152,193119,049 127.8%  
Other income Rs m3,5771,132 315.9%   
Total revenues Rs m155,769120,181 129.6%   
Gross profit Rs m28,26428,475 99.3%  
Depreciation Rs m13,2285,388 245.5%   
Interest Rs m1,142911 125.4%   
Profit before tax Rs m17,47023,308 75.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5015,644 44.3%   
Profit after tax Rs m14,16618,292 77.4%  
Gross profit margin %18.623.9 77.6%  
Effective tax rate %14.324.2 59.1%   
Net profit margin %9.315.4 60.6%  
BALANCE SHEET DATA
Current assets Rs m108,14182,005 131.9%   
Current liabilities Rs m38,32260,720 63.1%   
Net working cap to sales %45.917.9 256.6%  
Current ratio x2.81.4 208.9%  
Inventory Days Days9773 132.6%  
Debtors Days Days7498 75.7%  
Net fixed assets Rs m109,41183,703 130.7%   
Share capital Rs m1,6101,024 157.2%   
"Free" reserves Rs m140,68286,421 162.8%   
Net worth Rs m142,29287,445 162.7%   
Long term debt Rs m36,62125,551 143.3%   
Total assets Rs m228,606180,653 126.5%  
Interest coverage x16.326.6 61.3%   
Debt to equity ratio x0.30.3 88.1%  
Sales to assets ratio x0.70.7 101.0%   
Return on assets %6.710.6 63.0%  
Return on equity %10.020.9 47.6%  
Return on capital %10.022.0 45.3%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69142,683 121.1%   
Fx outflow Rs m21,03311,242 187.1%   
Net fx Rs m30,65831,441 97.5%   
CASH FLOW
From Operations Rs m14,6289,193 159.1%  
From Investments Rs m-8,540-9,737 87.7%  
From Financial Activity Rs m-3,855515 -748.5%  
Net Cashflow Rs m2,431-29 -8,383.1%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 21, 2018 (Close)

TRACK CIPLA

CIPLA - DIVIS LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS